Marché de la greffe de cornée au Moyen-Orient et en Afrique – Tendances et prévisions de l’industrie jusqu’en 2031

Analyse et taille du marché de la greffe de cornée au Moyen-Orient et en Afrique

Le marché des implants cornéens au Moyen-Orient et en Afrique est influencé par plusieurs facteurs, notamment la prévalence croissante des maladies cornéennes, le vieillissement croissant de la population, les progrès technologiques, la demande croissante de procédures mini-invasives, la sensibilisation croissante à la transplantation cornéenne, les initiatives et financements gouvernementaux, l'adoption croissante des lentilles hybrides et toriques, la popularité croissante des procédures de réticulation, l'élargissement des indications pour les implants cornéens et un paysage concurrentiel qui favorise l'innovation. Ces facteurs stimulent collectivement la demande d'implants cornéens, en particulier dans les pays développés, car les patients recherchent des traitements efficaces pour les troubles de la vision et des affections telles que le kératocône, la dystrophie de Fuchs et la kératopathie bulleuse pseudophaque.

Data Bridge Market Research analyse que le marché de la greffe de cornée au Moyen-Orient et en Afrique devrait atteindre 31,28 millions USD d'ici 2031, contre 21,86 millions USD en 2023, avec un TCAC de 4,6 % au cours de la période de prévision de 2024 à 2031.

Définition du marché

Le marché de la greffe de cornée fait référence au domaine médical axé sur les interventions chirurgicales qui remplacent les cornées endommagées ou malades par du tissu donneur sain. Les greffes de cornée, également appelées kératoplasties, sont réalisées pour restaurer la vision chez les patients souffrant de pathologies telles que le kératocône, les cicatrices cornéennes, les infections ou le dysfonctionnement endothélial cornéen. Le marché englobe divers types d'interventions de transplantation, notamment la kératoplastie pénétrante (greffe de cornée pleine épaisseur) et la kératoplastie endothéliale (greffe d'épaisseur partielle), et est soutenu par les progrès des techniques chirurgicales, la disponibilité des tissus donneurs et l'amélioration des soins postopératoires. Alors que les troubles oculaires deviennent plus fréquents à l'échelle mondiale et que les innovations technologiques améliorent le taux de réussite des interventions chirurgicales, le marché de la greffe de cornée continue de croître, répondant à la demande croissante de restauration de la vision.

Dynamique du marché de la greffe de cornée au Moyen-Orient et en Afrique :

Cette section traite de la compréhension des moteurs, des avantages, des opportunités, des contraintes et des défis du marché. Tout cela est discuté en détail ci-dessous :

Conducteurs

• Prévalence croissante des maladies oculaires

La prévalence croissante des maladies oculaires est un facteur important sur le marché de la greffe de cornée au Moyen-Orient et en Afrique, car des pathologies telles que le kératocône, la dystrophie endothéliale de Fuchs et les cicatrices cornéennes dues à des infections ou à des traumatismes deviennent plus courantes. Ces maladies peuvent entraîner une déficience visuelle grave ou la cécité, ce qui entraîne une demande croissante de greffes de cornée en tant que traitement réparateur. L'augmentation des troubles oculaires est souvent liée à des facteurs tels que le vieillissement de la population, des taux plus élevés de diabète et une exposition accrue aux polluants environnementaux et aux rayons UV, qui peuvent endommager la cornée. En outre, les progrès des techniques de diagnostic conduisent à une détection plus précoce de ces maladies, ce qui permet des interventions rapides, notamment la greffe de cornée. En outre, une meilleure connaissance de la santé de la cornée et la disponibilité de techniques chirurgicales améliorées, telles que la kératoplastie endothéliale à membrane de Descemet (DMEK) et la kératoplastie endothéliale automatisée par décollement de Descemet (DSAEK), contribuent à l'acceptation croissante des greffes de cornée. Alors que le fardeau des maladies oculaires continue de croître dans le monde entier, le besoin de solutions efficaces comme les greffes de cornée devrait augmenter, alimentant la croissance du marché.

Par exemple,

• In June 2023, according to the article published in NCBI, a study was conducted to investigate the prevalence of keratoconus in a large German cohort and to evaluate possible associated factors. Keratoconus appears to be a rare corneal disease with a prevalence previously estimated at 1:2000. However, in recent relatively small studies, a higher prevalence was found. Prevalence is reported from 1: 6000 for US citizens, 1:1000 for Israeli adolescents, up to 1:20 for Saudi-Arabian Children. Newer studies detected prevalence estimates of 1:191 in New Zealand high school students. A prevalence of up to 1:84 was detected for young Australian adults. The prevalence of keratoconus treatment in the German population is approximately tenfold higher than previously reported in the literature using the latest technologies, namely Scheimpflug imaging, which act as a driver in the growth of the market.

Rising Geriatric Population

The rising geriatric population is a key driver in the Middle East and Africa corneal transplant market, as older adults are more susceptible to various eye conditions that can lead to corneal damage and the need for transplants. Age-related eye diseases, such as Fuchs' endothelial dystrophy, bullous keratopathy, and other degenerative corneal disorders, become more prevalent with advancing age, significantly increasing the demand for corneal transplants. Also, older adults are more likely to experience complications from cataract surgery or develop chronic conditions like diabetes, which can further contribute to corneal deterioration. As the Middle East and Africa population ages, the number of individuals requiring corneal transplants is expected to rise, particularly in regions with rapidly aging demographics. This trend is further fueled by increased awareness about the availability and success rates of corneal transplants, as well as advancements in surgical techniques that offer better outcomes and faster recovery times for older patients. As a result, the growing geriatric population is a major factor driving the expansion of the Middle East and Africa corneal transplant market, highlighting the need for accessible and effective treatment options for age-related corneal diseases.

Opportunity

• Rise in Healthcare Infrastructure

The rise in healthcare infrastructure offers significant opportunities for the Middle East and Africa corneal transplant market by expanding access to transplant services. Enhanced infrastructure leads to the establishment of more hospitals and specialized clinics, making corneal transplants more accessible to a broader population. Improved facilities in underserved or rural areas ensure that patients who previously had limited access to specialized eye care can now receive essential transplant services.

Modernized healthcare facilities are equipped with advanced surgical technologies and diagnostic tools, which directly improve the success rates of corneal transplants and minimize complications. Specialized centers within these advanced systems provide focused expertise and resources, further enhancing surgical outcomes and patient care. The increased capacity of these facilities also supports a higher volume of transplant procedures, effectively addressing patient demand and reducing waiting times.

 For instance,

• In April 2024, according to the article ‘The Rise of Hospital Infrastructure & Modernization Updates,’ the U.S. boasts of a robust healthcare infrastructure consisting of over 6,000 hospitals and thousands of small clinics, offering more than a million hospital beds to patients. This infrastructure encompasses a variety of essential elements, such as advanced research labs, cutting-edge technology, and a wide range of medical equipment. Moreover, the federal government has been providing funds for the continuous modernization of the country’s healthcare infrastructure
• In August 2023, according to JLL India, India has been welcoming more investments and innovation to deal with future life-threatening diseases and pandemics that, in turn, help in growing the country’s healthcare and life sciences sector

Restraint/Challenge

• The High Cost of Corneal Transplant Surgery

The high cost of corneal transplant surgery acts as a significant restraint on the growth of the Middle East and Africa corneal transplant market by limiting patient access and affordability, particularly in low- and middle-income countries. Corneal transplant procedures, including traditional Penetrating Keratoplasty (PK) and advanced techniques like Descemet’s Membrane Endothelial Keratoplasty (DMEK) or Descemet’s Stripping Automated Endothelial Keratoplasty (DSAEK), often involve substantial expenses not only for the surgical procedure itself but also for the associated costs of preoperative assessments, postoperative care, medications, and follow-up visits. Also, the cost of obtaining donor corneas, whether through eye banks or commercial sources, further contributes to the financial burden. In many regions, particularly those with limited healthcare infrastructure, these costs are exacerbated by a lack of insurance coverage or inadequate reimbursement policies, making corneal transplants financially inaccessible to a large portion of the population. Furthermore, the need for specialized surgical expertise and advanced equipment increases the overall expense, thereby restricting the availability of these procedures to well-equipped medical centers in urban areas. Consequently, the high costs associated with corneal transplant surgery hinder market growth by reducing the potential patient pool, especially in underserved regions where the burden of corneal diseases is often most significant and access to affordable healthcare is limited.

Recent Developments

• In January 2024, Carl Zeiss India's Medical Technology Division showcased Cataract and Refractive Workflow at Phaco Festival by Nethradhama Super Speciality, Bengaluru. At the Phaco Festival, the spotlight shined on ZEISS's transformative impact on the Cataract and Corneal Refractive Workflows.
• In June 2024, CorneaGen today announces the commercial launch of Corneal Tissue Addition for Keratoplasty (CTAK), an innovative and extremely effective solution to corneal contouring for keratoconic eyes. Developed by CorneaGen in partnership with CTAK LLC and Ziemer, CTAK provides patient ready, gamma-irradiated sterile, non-immunogenic corneal tissue segments, laser cut and customized to patients’ specific cone severity and location
• In January 2024, Seattle-based CorneaGen is excited to announce an expansion of their eye recovery services throughout northern and southern California. Through this expansion of service, CorneaGen will now provide both eye recovery and processing services of donor tissue for facilities throughout the state, resulting in an even better experience for the patients, families, and staff of their California partner facilities.
• In August 2024, ZEISS extends its global refractive industry momentum with more than 10 million eyes treated with ZEISS SMILE and ZEISS SMILE pro; ZEISS announces first treatment in the CE market for hyperopia with lenticule extraction using ZEISS SMILE pro technology

Middle East and Africa Corneal Transplant Market Scope

The Middle East and Africa corneal transplant market is segmented into eight notable segments based on procedure type, type, donor type, graft type, surgery type, indication, gender, age group, and end user. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the differences in your target markets.

Procedure Type

• Endothelial Keratoplasty
•  Penetrating Keratoplasty
•  Anterior Lamellar Keratoplasty (ALK)
•  Corneal Limbal Stem Cell Transplant
•  Artifical Cornea Transplant
•  Others

On the basis of procedure type, the market is segmented into endothelial keratoplasty, penetrating keratoplasty, Anterior Lamellar Keratoplasty (ALK), corneal limbal stem cell transplant, artifical cornea transplant and others.

Type

• Human Cornea
• Synthetic

On the basis of type, the market is segmented into human cornea and synthetic.

Donor Type

• Allograft
• Autograft

On the basis of donor type, the market is segmented into allograft and autograft.

Graft Type

• Partial Thickness Grafts (Lamellar)
• Full Thickness Grafts (Penetrating)

On the basis of graft type, the market is segmented into partial thickness grafts (lamellar), full thickness grafts (penetrating).

Surgery Type

• Conventional Surgery
• Laser-Assisted Surgery

On the basis of surgery type, the market is segmented into conventional surgery and laser-assisted surgery.

Indication

• Fuch's Endothelial Dystrophy
•  Infectious Keratitis
•  Bullous Keratopathy
•  Keratoconus
•  Regraft Procedures
•  Corneal Scarring
•  Corneal Ulcers
•  Others

On the basis of indication, the market is segmented into fuch's endothelial dystrophy, infectious keratitis, bullous keratopathy, keratoconus, regraft procedures, corneal scarring, corneal ulcers and others.

Gender

• Female
• Male

On the basis of gender, the market is segmented into female and male.

Age Group

• Geriatric
•  Adult
•  Pediatric

On the basis of age group, the market is segmented into geriatric, adult and pediatric.

End User

• Hospitals,
• Eye Clinics,
•  Ambulatory Surgical Centers,
•  Academic & Research Institutes
• Others

On the basis of end user, the market is segmented into hospitals, eye clinics, ambulatory surgical centers, academic & research institutes and others.

Middle East and Africa Corneal Transplant Market Regional Analysis/Insights

Middle East and Africa corneal transplant market is analyzed, and market size insights and trends are provided based on procedure type, type, donor type, graft type, surgery type, indication, gender, age group, and end user as referenced above.

The countries covered in this market report are South Africa, Saudi Arabia, U.A.E., Egypt, Israel, Rest of Middle East and Africa.

South Africa is expected to dominate in the Middle East and Africa market due to its advanced healthcare infrastructure, significant consumer demand for eye treatments, strong pharmaceutical industry, extensive research and development efforts, and well-established distribution networks, making it a hub for innovation.

The country section of the report also provides individual market impacting factors and changes in market regulation that impact the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of regional brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Middle East and Africa Corneal Transplant Market Share Analysis

The Middle East and Africa corneal transplant market is segmented into eight notable segments based on procedure type, donor type, graft type, surgery type, indication, gender, age group, and end user.

The Middle East and Africa corneal transplant market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, regional presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, and application dominance. The above data points provided are only related to the companies' focus on the Middle East and Africa corneal transplant market.

Certains des principaux acteurs opérant sur le marché de la transplantation cornéenne au Moyen-Orient et en Afrique sont ZEISS Group (Carl Zeiss Meditec AG.), Alcon, CorneaGen, Ziemer Ophthalmic Systems AG, RUMEX International Co., entre autres.

SKU-72889